Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, And Y tetanus toxoid conjugate vaccine (MenACWY-TT)

International Journal of Infectious Diseases

Volumn 17, Issue 3, 2013, Pages

  Østergaard, Lars ^a   Van der Wielen, Marie ^b,c   Bianco, Veronique ^b,c   Miller, Jacqueline M ^b,c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Adolescents; Antibody persistence; Conjugate vaccines; Neisseria meningitidis; Tetravalent meningococcal vaccine

Indexed keywords

MENINGOCOCCUS VACCINE; TETANUS TOXOID;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MALE; NEISSERIA MENINGITIDIS; PHASE 2 CLINICAL TRIAL; SEROLOGY; VACCINATION;

ADOLESCENT; ANIMALS; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; FEMALE; HUMANS; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; RABBITS; TETANUS TOXOID; VACCINATION; YOUNG ADULT;

EID: 84874494263     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.10.001     Document Type: Article

References (23)

1. Trotter C.L., Chandra M., Cano R., Larrauri A., Ramsay M.E., Brehony C., et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007, 3:27-36.
2. Cohn A.C., MacNeil J.R., Harrison L.H., Hatcher C., Theodore J., Schmidt M., et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010, 50:184-191.
3. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl 2):B51-B63.
4. Miller E., Salisbury D., Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001, 20(Suppl 1):S58-S67.
5. De Wals P., De Serres G., Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001, 285:177-181.
6. Booy R., Jelfs J., El Bashir H., Nissen M.D. Impact of meningococcal C conjugate vaccine use in Australia. Med J Aust 2007, 186:108-109.
7. Macneil J.R., Cohn A.C., Zell E.R., Schmink S., Miller E., Clark T., et al. Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J 2011, 30:451-455.
8. MacDonald N.E., Halperin S.A., Law B.J., Forrest B., Danzig L.E., Granoff D.M. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998, 280:1685-1689.
9. Auckland C., Gray S., Borrow R., Andrews N., Goldblatt D., Ramsay M., et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006, 194:1745-1752.
10. Bilukha O.O., Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005, 54(RR-7):1-21.
11. Updated Recommendations for Use of Meningococcal Conjugate Vaccines-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011;60:72-6.
12. Cohn A. Optimizing the adolescent meningococcal vaccination program. US Centers for Disease Control and Prevention; October 27, 2010. Available at: (accessed June 6, 2011). http://www.cdc.gov/vaccines/ed/ciinc/downloads/Dec_10/Cohn.pptx.
13. Østergaard L., Lebacq E., Poolman J., Maechler G., Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009, 27:161-168.
14. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997, 4:156-167.
15. Borrow R., Balmer P., Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005, 23:2222-2227.
16. Inadvertent misadministration of meningococcal conjugate vaccine-United States, June-August 2005. MMWR Morb Mortal Wkly Rep 2006, 55:1016-1017. Centers for Disease Control and Prevention.
17. Poolman J.T., De Vleeschauwer I., Durant N., Devos N., Feron C., Lestrate P., et al. Measurement of functional anti-meningococcal serogroup A activity using strain 3125 as the target strain for serum bactericidal assay. Clin Vaccine Immunol 2011, 18:1108-1117.
18. Snape M.D., Perrett K.P., Ford K.J., John T.M., Pace D., Yu L.M., et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008, 299:173-184.
19. Wilder-Smith A., Goh K.T., Barkham T., Paton N.I. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis 2003, 36:679-683.
20. Vu D.M., Welsch J.A., Zuno-Mitchell P., Dela Cruz J.V., Granoff D.M. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis 2006, 193:821-828.
21. ® among healthy adolescents. Hum Vaccin 2010, 6:881-887.
22. Ceesay S.J., Allen S.J., Menon A., Todd J.E., Cham K., Carlone G.M., et al. Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization. J Infect Dis 1993, 167:1212-1216.
23. Zangwill K.M., Stout R.W., Carlone G.M., Pais L., Harekeh H., Mitchell S., et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J Infect Dis 1994, 169:847-852.